A new paper suggests that women with breast cancer, also receiving treatment with GLP-1, had a substantially reduced risk of dying over 10 years (up to 91% lower, for women who used GLP-1 to manage diabetes versus those using other diabetes medications)
A large scientific review analyzing 37 clinical trials found that people taking L-Carnitine experienced only modest weight lossaround 11.2 kgand mostly when combined with diet control and exercise
Some patients research the data, see that tirzepatide produces roughly 5 to 7 percentage points more body weight loss on average than semaglutide, and want access to that additional potential
But for the people who qualify for and are taking GLP-1s to lose weight, it seems like they just cant win
By keeping track of your progress, you can pinpoint when adjustments are needed
Furthermore, these findings are supported by previous studies that have shown the importance of RhoA/ROCK signaling in OPC differentiation (Baer et al., 2009
